These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Synthesis and structural characterisation of bismuth(III) hydroxamates and their activity against Helicobacter pylori. Pathak A; Blair VL; Ferrero RL; Junk PC; Tabor RF; Andrews PC Dalton Trans; 2015 Oct; 44(38):16903-13. PubMed ID: 26352159 [TBL] [Abstract][Full Text] [Related]
10. Synthetic investigation, physicochemical characterization and antibacterial evaluation of ternary Bi(III) systems with hydroxycarboxylic acid and aromatic chelator substrates. Nday CM; Halevas E; Tsiaprazi-Stamou A; Eleftheriadou D; Hatzidimitriou A; Jackson G; Reid D; Salifoglou A J Inorg Biochem; 2017 May; 170():98-108. PubMed ID: 28231455 [TBL] [Abstract][Full Text] [Related]
11. Bismuth(III) complexes derived from α-amino acids: the impact of hydrolysis and oxido-cluster formation on their activity against Helicobacter pylori. Busse M; Border E; Junk PC; Ferrero RL; Andrews PC Dalton Trans; 2014 Dec; 43(48):17980-90. PubMed ID: 25310996 [TBL] [Abstract][Full Text] [Related]
12. Comparative stability, cytotoxicity and anti-leishmanial activity of analogous organometallic Sb(V) and Bi(V) acetato complexes: Sb confirms potential while Bi fails the test. Duffin RN; Blair VL; Kedzierski L; Andrews PC J Inorg Biochem; 2018 Dec; 189():151-162. PubMed ID: 30267965 [TBL] [Abstract][Full Text] [Related]
13. Structural motifs in phenylbismuth heterocyclic carboxylates--secondary interactions leading to oligomers. Anjaneyulu O; Maddileti D; Kumara Swamy KC Dalton Trans; 2012 Jan; 41(3):1004-12. PubMed ID: 22105914 [TBL] [Abstract][Full Text] [Related]
14. Do bismuth complexes hold promise as antileishmanial drugs? Ong YC; Kedzierski L; Andrews PC Future Med Chem; 2018 Jul; 10(14):1721-1733. PubMed ID: 29961352 [TBL] [Abstract][Full Text] [Related]
15. Homo- and heteroleptic bismuth(III/V) thiolates from N-heterocyclic thiones: synthesis, structure and anti-microbial activity. Luqman A; Blair VL; Brammananth R; Crellin PK; Coppel RL; Andrews PC Chemistry; 2014 Oct; 20(44):14362-77. PubMed ID: 25224757 [TBL] [Abstract][Full Text] [Related]
16. Alkyl gallium(III) quinolinolates: A new class of highly selective anti-leishmanial agents. Duffin RN; Blair VL; Kedzierski L; Andrews PC Eur J Med Chem; 2020 Jan; 186():111895. PubMed ID: 31771825 [TBL] [Abstract][Full Text] [Related]
17. Influence of hydroxycarboxylic acids on the water solubility of various bismuth compounds. Heinemann A; Strugala G; Elsenhans B Arzneimittelforschung; 1995 Jan; 45(1):48-51. PubMed ID: 7893269 [TBL] [Abstract][Full Text] [Related]
18. The thiol-based reduction of Bi(V) and Sb(V) anti-leishmanial complexes. Duffin RN; Stephens LJ; Blair VL; Kedzierski L; Andrews PC J Inorg Biochem; 2021 Aug; 221():111470. PubMed ID: 33971522 [TBL] [Abstract][Full Text] [Related]
19. Expanding the family of heterobimetallic Bi-Rh paddlewheel carboxylate complexes via equatorial carboxylate exchange. Sunderland TL; Berry JF Dalton Trans; 2016 Jan; 45(1):50-5. PubMed ID: 26599620 [TBL] [Abstract][Full Text] [Related]
20. Coordination of thiosemicarbazones and bis(thiosemicarbazones) to bismuth(III) as a strategy for the design of metal-based antibacterial agents. Lessa JA; Reis DC; Da Silva JG; Paradizzi LT; da Silva NF; Carvalho Mde F; Siqueira SA; Beraldo H Chem Biodivers; 2012 Sep; 9(9):1955-66. PubMed ID: 22976983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]